嵌合抗原受体的发展现状及其临床应用  

Current development and clinical application of chimeric antigen receptor

作　　者：黄敏[1] 刘传苗[1] Huang Min Liu Chuanmiao(Department of Infection, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui, Chin)

机构地区：[1]蚌埠医学院第一附属医院感染科,安徽蚌埠233004

出　　处：《国际流行病学传染病学杂志》2017年第1期57-61,共5页International Journal of Epidemiology and Infectious Disease

基　　金：国家自然科学基金（81472656）;蚌埠医学院2015年度研究生科研创计划（Byycx1514）

摘　　要：嵌合抗原受体（CAR）T细胞是近几年发展起来的治疗肿瘤的细胞免疫学方法之一。CAR—T细胞不但成功治疗晚期难治性恶性B细胞肿瘤，而且已经用于治疗其他的实体肿瘤。虽然CAR—T细胞为临床治疗恶性肿瘤提供新的免疫学方法，但是仍然有其局限性，比如细胞因子风暴，CAR-T细胞的脱靶效应等。而CAR—NK细胞不产生IL-6，因而不存在细胞因子风暴的问题，相比CAR—T细胞有优势，但是CAR—NK细胞对实体肿瘤治疗的效果仍然不理想。本文综述CAR—T细胞和CAR—NK细胞的发展以及其临床应用。Chimeric antigen receptor （CAR） T cells is one of the treatment methods of cellular immunology developed in recent years. CAR-T cells have not only successfully used in treating advanced refractory B cell malignancies, but also in solid tumors. Although CAR-T cell technology provides a new immunological method for the treatment of malignant tumors, it has its limitations such as cytokine release syndrome , ＂on-target/off-tumor＂ side effect and so on. CAR-NK cells donlt secrecte IL-6, so there is no cytokine storm. CAR-NK cells have more advantages than CAR-T cells, yet the effect of CAR-NK ceils on solid tumor treatment is not ideal. The development of CAR-T cells and CAR-NK cells and their clinical applications are described in this review.

关 键 词：T淋巴细胞 嵌合抗原受体 肿瘤 

分 类 号：R730.51[医药卫生—肿瘤]